Drugs / PROT-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06981299 | May → Dec 2025 | — | Protego Biopharma Pty Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PROT-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06981299 ↗ |
| Modality | Small molecule | “Orally bioavailable small molecule kinetic stabilizer of lambda light chains (λLCs).” NCT06981299 ↗ |
| Route | Oral | “Orally bioavailable” NCT06981299 ↗ |